QuantRx Biomedical Corporation Announces FluoroPharma to Present Results of CardioPET Phase I Trial at Society of Nuclear Medicine High Country Conference

DOYLESTOWN, PA--(Marketwire - February 21, 2008) - QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, today announced that Dr. David Elmaleh, Chairman and Chief Scientific Founder of FluoroPharma, will present findings from the company's Phase I trial for CardioPET, a metabolic cardiac imaging agent for the assessment of coronary artery disease at the Society of Nuclear Medicine's (SNM) annual High Country Nuclear Medicine Conference in Denver, Colorado. During his presentation, Dr. Elmaleh will discuss the results of the recently completed trial, including findings in healthy subjects and patients with CAD. The presentation will be part of the "Clinical Trials Update" session on Saturday, March 1, 2008.